Nitinol Technologies CE-marks vena cava filter:
This article was originally published in Clinica
Executive Summary
Nitinol Medical Technologies has CE-marked its Simon Nitinol vena cava filter. The thermal shape-memory filter is designed to prevent pulmonary embolism which occurs when a blood clot lodges in the vessels supplying blood to the lungs. The company, which estimated that the condition causes about 150,000 deaths each year in the US, claimed that the device holds the number two position in sales of vena cava filters worldwide.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.